Literature DB >> 29021510

Treatment of rheumatoid arthritis with biological agents - as a typical and common immune-mediated inflammatory disease.

Tsutomu Takeuchi1.   

Abstract

Molecules involved in the disease process facilitated our understanding of pathogenesis of the disease with unknown etiology such as immune-mediated and inflammatory diseases. Moreover, the targeted therapies against the proposed molecular targets by biological agents provide enormous benefits to the patients and societies. Here, I will review recent progress of the biological treatment in the immune-inflammatory diseases by focusing on the rheumatoid arthritis, the disease characterized by persistent polyarthritis leading to joint destruction and disability with autoimmune features, as a role model.

Entities:  

Keywords:  biologics; cytokines; immune-mediated inflammatory diseases; rheumatoid arthritis; therapy

Mesh:

Substances:

Year:  2017        PMID: 29021510      PMCID: PMC5743860          DOI: 10.2183/pjab.93.038

Source DB:  PubMed          Journal:  Proc Jpn Acad Ser B Phys Biol Sci        ISSN: 0386-2208            Impact factor:   3.493


  28 in total

Review 1.  Autoimmune diseases.

Authors:  A Davidson; B Diamond
Journal:  N Engl J Med       Date:  2001-08-02       Impact factor: 91.245

Review 2.  The Japanese experience with biologic therapies for rheumatoid arthritis.

Authors:  Tsutomu Takeuchi; Hideto Kameda
Journal:  Nat Rev Rheumatol       Date:  2010-09-28       Impact factor: 20.543

Review 3.  Biomarkers as a treatment guide in rheumatoid arthritis.

Authors:  Tsutomu Takeuchi
Journal:  Clin Immunol       Date:  2017-07-20       Impact factor: 3.969

Review 4.  Interleukin-6: from basic science to medicine--40 years in immunology.

Authors:  Tadamitsu Kishimoto
Journal:  Annu Rev Immunol       Date:  2005       Impact factor: 28.527

Review 5.  Rheumatoid arthritis.

Authors:  Josef S Smolen; Daniel Aletaha; Iain B McInnes
Journal:  Lancet       Date:  2016-05-03       Impact factor: 79.321

Review 6.  Novel Immunotherapeutic Avenues for Rheumatoid Arthritis.

Authors:  Luca Semerano; Emeline Minichiello; Natacha Bessis; Marie-Christophe Boissier
Journal:  Trends Mol Med       Date:  2016-02-12       Impact factor: 11.951

Review 7.  Revolutionary change in rheumatoid arthritis management with biological therapy.

Authors:  Tsutomu Takeuchi
Journal:  Keio J Med       Date:  2011

8.  Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial.

Authors:  Norihiro Nishimoto; Kazuyuki Yoshizaki; Nobuyuki Miyasaka; Kazuhiko Yamamoto; Shinichi Kawai; Tsutomu Takeuchi; Jun Hashimoto; Junichi Azuma; Tadamitsu Kishimoto
Journal:  Arthritis Rheum       Date:  2004-06

9.  Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study).

Authors:  Keisuke Izumi; Yuko Kaneko; Misato Hashizume; Keiko Yoshimoto; Tsutomu Takeuchi
Journal:  PLoS One       Date:  2015-12-23       Impact factor: 3.240

10.  Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study.

Authors:  T W J Huizinga; Philip G Conaghan; Emilio Martin-Mola; Georg Schett; Howard Amital; Ricardo M Xavier; Orrin Troum; Maher Aassi; Corrado Bernasconi; Maxime Dougados
Journal:  Ann Rheum Dis       Date:  2014-08-28       Impact factor: 19.103

View more
  2 in total

1.  Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomised controlled study (the second year of the SURPRISE study).

Authors:  Yuko Kaneko; Masaru Kato; Yoshiya Tanaka; Masayuki Inoo; Hitomi Kobayashi-Haraoka; Koichi Amano; Masayuki Miyata; Yohko Murakawa; Hidekara Yasuoka; Shintaro Hirata; Eiichi Tanaka; Nobuyuki Miyasaka; Hisashi Yamanaka; Kazuhiko Yamamoto; Tsutomu Takeuchi
Journal:  Ann Rheum Dis       Date:  2018-05-31       Impact factor: 19.103

2.  ASP5094, a humanized monoclonal antibody against integrin alpha-9, did not show efficacy in patients with rheumatoid arthritis refractory to methotrexate: results from a phase 2a, randomized, double-blind, placebo-controlled trial.

Authors:  Tsutomu Takeuchi; Yoshiya Tanaka; Jay Erdman; Yuichiro Kaneko; Masako Saito; Chieri Higashitani; Ronald Smulders; Christopher Lademacher
Journal:  Arthritis Res Ther       Date:  2020-10-21       Impact factor: 5.156

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.